GlassScriptPhysician profile
Erica A Quigley
NPI 1952935082
$4,684.24
in general payments reported to CMS, 2019-2025
24 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $228 · 2023: $952 · 2024: $1,886 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,354.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.46 | 2022-2025 | |
| Amgen INC. | $748.34 | 2022-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $612.15 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $436.79 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $406.05 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $261.22 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $216.49 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.61 | 2022-2024 | Jardiance, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $117.42 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $113.24 | 2023-2025 | Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $95.39 | 2022-2024 | |
| Medtronic, INC. | $90.00 | 2021 | |
| Astellas Pharma US INC | $74.55 | 2023-2025 | Veozah |
| Axsome Therapeutics, INC. | $74.06 | 2024-2025 | Auvelity, Symbravo |
| Insulet Corporation | $68.98 | 2025 | Omnipod |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $64.99 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $64.95 | 2022-2023 | Camzyos |
| Exact Sciences Corporation | $56.11 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $54.01 | 2024-2025 | Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $26.21 | 2021-2022 | |
| Dynavax Technologies Corporation | $23.37 | 2025 | Heplisav-B |
| Harmony Biosciences LLC | $22.86 | 2024 | |
| Merck Sharp & Dohme LLC | $15.76 | 2023 | Verquvo |
| Xeris Pharmaceuticals, INC. | $13.23 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Quigley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.